NASDAQ$OKUR

OnKure Therapeutics Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Headline financials

EPS (adj)

-$0.60

Previous: -$0.53-13.2%
Capital Expenditures

$172K

Previous: $44K+290.9%
Free Cash Flow

-$9.22M

Previous: -$9.04M-2.0%
Net Income

-$15.1M

Previous: -$13M-15.9%
Operating Income

-$16.1M

Previous: -$13M-23.9%
Cash & Equivalents

$30.4M

Previous: $121M-74.9%
Total Assets

$98.9M

Previous: $144M-31.5%
Stock-Based Comp

$1.16M

Previous: $1.11M+4.5%

Revenue & EPS history

Reneo Pharmaceuticals · Revenue · Quarterly

$458K

Q1 2026
Beat estimate in 0 of 1 quarters(0%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+2.2%

Avg return

Earnings day

+0.9%

Avg return

5 days after

+3.6%

Avg return

30 days after

52%

11 / 21 earnings

Positive

+21.2%

Q2 2025

Best reaction

-10.3%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.7%-15.0%-6.3%
Q3 2025-5.5%-2.5%-3.2%
Q2 2025+21.2%+24.6%+20.2%
Q1 2025+12.5%+7.5%+21.0%
Q4 2024+3.7%+4.8%-40.0%
Q3 2024+3.2%+1.8%-16.7%
Q2 2024+9.7%+15.7%+5.2%
Q1 2024+2.4%+3.0%+0.6%
Q4 2023+3.0%+3.6%+1.2%
Q3 2023-0.9%+5.6%+21.1%
Q2 2023-6.3%-15.1%+7.1%
Q1 2023-1.4%-0.9%+79.3%
Q4 2022-10.3%-1.0%+65.1%
Q3 2022-3.0%-8.6%-35.4%
Q2 2022-3.0%+4.1%+34.6%
Q1 2022-5.9%-10.8%-28.2%
Q4 2021-1.4%-6.8%-34.7%
Q3 2021+14.8%+5.7%-13.2%
Q2 2021+0.1%-3.2%+2.0%
Q4 2020+7.5%+2.9%-2.3%
Q1 2021+7.5%+2.9%-2.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro